Why a Certificate of Analysis Has Limits

A certificate of analysis has limits because it summarizes selected test results for a particular sample or batch under specified methods and acceptance criteria. It does not independently prove that the sample was collected correctly, that the certificate applies to every unit sold, that all relevant impurities were detected, that the product remained stable after testing, or that the finished product is clinically effective or suitable for a particular use.

Interpreting a certificate forms part of the evaluation of research peptides, where analytical results must be connected with sampling, batch identity, test methods, supplier reliability, manufacturing records, formulation, storage, and the questions the testing was designed to answer.

This article is provided for general educational purposes and explains analytical and quality-documentation concepts. It does not establish the regulatory status of any specific InStrips product or determine whether a particular product is appropriate for any person.

A certificate of analysis does not by itself establish finished-product identity, complete purity, batch-wide consistency, human absorption, clinical effectiveness, an appropriate dosage, or suitability for a particular use.

What Is a Certificate of Analysis?

A certificate of analysis, commonly abbreviated as COA, is a document summarizing test results associated with a specified material, sample, lot, or batch.

A COA may include:

• product or material name
• lot or batch number
• manufacturing or test date
• tests performed
• acceptance limits
• actual results
• laboratory information
• approval or signature

The content and reliability of certificates can vary substantially.

A COA Is a Summary Document

A certificate generally summarizes results rather than reproducing all underlying analytical information.

The complete record may also include:

• raw instrument data
• chromatograms
• spectra
• calculations
• sample-preparation records
• method-validation information
• system-suitability results
• laboratory deviations

A short certificate cannot display every detail needed for a full technical review.

The Certificate Applies to a Defined Sample

Testing is performed on a sample rather than every molecule or every finished unit in a batch.

The result is meaningful only when the sample adequately represents the material being described.

Sampling questions include:

• Who collected the sample?
• Where was it collected?
• Was the container selected randomly?
• Was the sample protected during transport?
• Could substitution or contamination occur?

A sophisticated analytical method cannot correct an unrepresentative or incorrectly identified sample.

Chain of Custody Matters

Chain of custody documents who possessed and handled the sample from collection through testing.

Weak chain of custody can create uncertainty about:

• sample identity
• tampering
• substitution
• storage
• transport conditions

A COA supplied by a seller may be accurate for the tested sample while still failing to prove that the tested sample came from the batch ultimately delivered to a buyer.

Lot and Batch Numbers Must Match

The lot or batch identifier on the certificate should correspond with the material being evaluated.

A mismatch may indicate that:

• another batch was tested
• an older certificate was reused
• the product was repackaged
• traceability is incomplete

Visual similarity between products does not establish that a certificate belongs to the current batch.

A Supplier COA Is Not Automatically Independent

A certificate may be issued by:

• the manufacturer
• the supplier
• a contract laboratory
• a buyer’s laboratory
• another third party

The relationship among the seller, sample collector, and laboratory affects how independence should be interpreted.

Third-party testing can reduce some conflicts, but independence alone does not establish method suitability, representative sampling, or complete testing.

Supplier Reliability Must Be Established

Quality systems may require more than collecting a supplier’s certificate.

Confidence in supplier results can depend on:

• initial qualification
• confirmation testing
• periodic requalification
• audit information
• performance history
• change notification
• investigation of discrepancies

A certificate should not be treated as automatically reliable merely because it uses formal formatting or includes a signature.

The Tests Performed Determine What the COA Can Show

A COA can answer only the questions addressed by its listed tests.

A certificate reporting chromatographic purity may not address:

• sequence identity
• counterion content
• water content
• residual solvents
• microbial quality
• endotoxin
• content uniformity
• stability

The absence of a failed result does not mean that untested attributes were acceptable.

Identity Testing and Purity Testing Are Different

Identity testing asks whether the material is the intended substance.

Purity testing asks how much of the detected sample corresponds to the main component relative to detectable related substances.

The relationship between peptide identity and purity matters because one favorable test cannot substitute for the other.

A Chromatographic Purity Percentage Has Context

A stated purity percentage may depend on:

• column
• mobile phase
• detector
• wavelength
• integration settings
• sample concentration
• run time

An impurity not separated, not detected, or not included in the calculation may not appear in the reported value.

Area Percentage Is Not Always Active-Peptide Content

A chromatographic area percentage describes detector response under a particular method.

It may not equal the percentage of active peptide by total sample weight because the sample can also contain:

• water
• counterions
• residual solvents
• inorganic material
• components with different detector responses

A “99 percent purity” statement should therefore not automatically be read as “99 percent active peptide by weight.”

Mass Spectrometry Has Limits

Mass spectrometry can support identification by showing a molecular mass consistent with the intended peptide.

It may not by itself establish:

• complete sequence order
• stereochemistry
• purity
• strength
• aggregation
• finished-product performance

A mass match is useful evidence rather than a complete quality evaluation.

Method Validation Matters

A validated analytical method is evaluated for its ability to perform its intended purpose.

Relevant characteristics may include:

• accuracy
• precision
• specificity
• linearity
• range
• detection capability
• robustness

A result generated by an unsuitable method may appear precise without measuring the intended attribute reliably.

Acceptance Limits Need Context

A certificate may show that a result “passes,” but the pass depends on the acceptance criterion selected.

Questions include:

• Who established the limit?
• Is it scientifically justified?
• Does it apply to the intended route?
• Does it address relevant impurities?
• Is it appropriate throughout shelf life?

A weak specification can produce a passing result without providing meaningful assurance.

Not Every Impurity Is Listed

A COA may report total impurities without identifying each individual component.

Peptide-related impurities can include:

• deletion sequences
• truncated peptides
• oxidized forms
• deamidated forms
• isomers
• aggregates

An unidentified impurity may have unknown biological activity or safety significance.

Residual Solvents May Require Separate Testing

Manufacturing can involve solvents that should be controlled appropriately.

A chromatographic peptide-purity test may not be designed to detect residual solvents.

The COA should identify whether suitable solvent testing was performed rather than assuming a purity result covers every manufacturing residue.

Water Content Can Affect Strength Calculations

Peptide materials may contain variable amounts of water.

Water can affect:

• total sample weight
• active-content calculations
• stability
• handling
• batch comparisons

A certificate that omits water content may provide an incomplete basis for calculating peptide amount by weight.

Counterion Content Can Affect Interpretation

A peptide salt includes a counterion contribution that may vary among materials.

Without counterion analysis, it may be difficult to determine:

• the complete salt composition
• active-peptide content
• comparability among batches
• the basis of the stated strength

This is particularly relevant when free-base and salt quantities are compared.

Microbial Testing Is a Separate Question

Chemical purity does not establish microbial quality.

Depending on the product and route, relevant testing may involve:

• microbial limits
• absence of specified organisms
• sterility
• endotoxin

A chemically pure material can still present contamination risks.

Sterility and Endotoxin Are Different Tests

Sterility testing examines whether viable microorganisms are detected under the test conditions.

Endotoxin testing examines bacterial components that can remain even when viable bacteria are absent.

A certificate showing one test should not be interpreted as proof of the other.

A Bulk-Material COA Is Not a Finished-Product COA

Testing the bulk peptide does not establish that the finished oral film, capsule, injection, nasal formulation, or topical product has the same characteristics.

Finished-product manufacturing introduces questions involving:

• content uniformity
• excipient compatibility
• release
• degradation
• microbial quality
• packaging

Evidence for a starting material cannot substitute automatically for finished-product testing.

Content Uniformity Requires Unit-Level Evidence

A bulk batch can have an acceptable assay while individual dosage units vary.

Unit variation may result from:

• poor mixing
• settling
• uneven film thickness
• variable filling
• cutting differences

A bulk certificate does not prove that every finished unit contains the same amount.

The COA Describes a Point in Time

Testing shows the sample’s condition when it was analyzed.

After testing, the material may be affected by:

• heat
• humidity
• oxygen
• light
• transport
• repackaging
• time

A valid release result does not guarantee that the product remains unchanged indefinitely.

Stability Requires More Than One Release Test

Stability evaluation generally examines how quality changes over time under defined conditions.

It may involve repeated testing of:

• identity
• assay
• purity
• degradation products
• water
• physical properties
• microbial quality

A single COA cannot replace a stability program.

Manufacturing Changes Can Make an Older COA Less Relevant

Changes in supplier, synthesis, purification, site, equipment, scale, or packaging may alter the product profile.

The importance of manufacturing differences in peptide evaluation means that a certificate from an earlier process may not describe later material adequately.

Formatting Does Not Prove Authenticity

A certificate can appear professional while containing inaccurate, altered, copied, or incomplete information.

Authenticity checks may involve:

• contacting the laboratory
• confirming the report number
• matching the lot
• checking dates
• reviewing signatures
• confirming the test scope

A laboratory logo or digital signature should not be the only basis for trust.

A COA Does Not Establish Clinical Effectiveness

A certificate may support chemical or microbiological characterization.

It does not show that the product:

• is absorbed in humans
• reaches an intended tissue
• engages a biological target
• improves symptoms
• improves function
• has an acceptable benefit-risk profile

Those conclusions require different forms of research.

A COA Does Not Determine Regulatory Status

A valid certificate can be required in some regulated contexts, but possession of a COA does not independently establish:

• FDA approval
• final compounding eligibility
• lawful marketing for every use
• an approved indication
• product equivalence

Analytical documentation and regulatory status answer different questions.

FDA Expectations for Supplier Certificates

FDA materials addressing supplier certificates emphasize that reliance on a COA may require establishing the supplier’s reliability, documenting methods and results, and periodically confirming performance rather than accepting the document without verification.

The FDA good-manufacturing-practice guidance for active pharmaceutical ingredients also places certificates within a broader quality system that includes specifications, testing, documentation, investigations, and manufacturing controls.

How to Review a COA

Useful questions include:

• Does the lot number match?
• Who collected the sample?
• Which laboratory performed the testing?
• Was the laboratory independent?
• Which tests were performed?
• Which methods were used?
• Are actual results shown?
• Were identity and purity both assessed?
• Does the certificate apply to the finished product?
• Is the document current and authentic?

These questions help define what confidence the certificate can reasonably support.

Final Perspective

A certificate of analysis can provide useful evidence about selected characteristics of a defined sample or batch. Its value depends on representative sampling, traceability, suitable methods, justified specifications, reliable laboratory work, supplier qualification, and an accurate connection with the material being evaluated.

The document cannot establish attributes that were not tested, guarantee every unit in a batch, predict future stability, or prove human effectiveness.

A COA should therefore be treated as one part of a larger quality record rather than a complete certificate of identity, safety, performance, regulatory status, and clinical value.